Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors Women diagnosed with stage 0 to III breast cancer at or before age 50 years who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results